Filtered By:
Source: Diabetes, Obesity and Metabolism
Drug: Insulin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 22 results found since Jan 2013.

Plasma proprotein ‐convertase‐subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
ConclusionsWe found that PCSK9 was inconsistently associated with CV events in populations with type 2 diabetes. The association may depend on the level of CV risk and the background treatment.
Source: Diabetes, Obesity and Metabolism - January 14, 2018 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, Philippe Gabriel Steg, Louis Potier, Youmna Ghaleb, Sandy Elbitar, Stephanie Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Tags: ORIGINAL ARTICLE Source Type: research

Plasma PCSK9 and Cardiovascular Events in Type 2 Diabetes
ConclusionsPCSK9 is inconsistently associated with CV events in populations with T2DM. The association may depend on the level of CV risk and the background treatment
Source: Diabetes, Obesity and Metabolism - December 5, 2017 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, P. Gabriel Steg, Louis Potier, Youmna Ghaleb, S El Bitar, S Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Hadjadj, Catheri Tags: ORIGINAL ARTICLE Source Type: research

Insulin Resistance and Cardiovascular Outcomes in the ORIGIN Trial
ConclusionsInsulin resistance may not promote cardiovascular outcomes in people with dysglycemia.
Source: Diabetes, Obesity and Metabolism - September 1, 2017 Category: Endocrinology Authors: Hertzel C. Gerstein, Ele Ferrannini, Matthew C. Riddle, Salim Yusuf, Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular safety of vildagliptin in patients with type 2 diabetes: a European multi ‐database, non‐interventional post‐authorization safety study
Abstract This non‐interventional, multi‐database, analytical cohort study assessed the cardiovascular (CV) safety of vildagliptin vs. other non‐insulin antidiabetic drugs (NIADs) using real‐world data from five European electronic healthcare databases. Patients with type 2 diabetes aged ≥18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (95% CIs) for the outcomes of interest (myocardial infarction [MI], acute coronary syndrome [ACS], stroke, congestive heart failure [CHF], individually and as a composite) were estimated using negative binomial regressio...
Source: Diabetes, Obesity and Metabolism - March 24, 2017 Category: Endocrinology Authors: R. Williams, F. de Vries, W. Kothny, C. Serban, S. Lopez ‐Leon, C. Chu, R. Schlienger Tags: BRIEF REPORT Source Type: research

Cardiovascular events and all ‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data
ConclusionsThe present meta‐analysis showed an association between SU therapy and a higher risk of major cardiovascular disease‐related events compared with other glucose lowering drugs. Results of ongoing RCTs, which should be available in 2018, will provide definitive results on the risk of cardiovascular events and all‐cause mortality associated with SUs vs other antihyperglycaemic drugs.
Source: Diabetes, Obesity and Metabolism - December 22, 2016 Category: Endocrinology Authors: Steve Bain, Eric Druyts, Chakrapani Balijepalli, Carl A. Baxter, Craig J. Currie, Romita Das, Richard Donnelly, Kamlesh Khunti, Haya Langerman, Paul Leigh, Gaye Siliman, Kristian Thorlund, Kabirraaj Toor, Jiten Vora, Edward J. Mills Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular events and all ‐cause mortality associated with sulfonylureas compared to other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data
ConclusionThis meta‐analysis shows an association between sulfonylurea therapy and a higher risk of major cardiovascular disease‐related events compared to other antihyperglycaemic drugs. Results of ongoing RCTs, which should be available in 2018, will provide definitive results on the risk of cardiovascular events and all‐cause mortality associated with sulfonylureas versus other antihyperglycaemic drugs.
Source: Diabetes, Obesity and Metabolism - October 31, 2016 Category: Endocrinology Authors: Steve Bain, Eric Druyts, Chakrapani Balijepalli, Carl A Baxter, Craig Currie, Romita Das, Richard Donnelly, Kamlesh Khunti, Haya Langerman, Paul Leigh, Gaye Siliman, Kristian Thorlund, Kabirraaj Toor, Jiten Vora, Edward J Mills Tags: Original Article Source Type: research

Cardiovascular safety of glucose ‐lowering agents as add‐on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register
ConclusionsThis nationwide observational study showed that second‐line treatment with TZD and DPP‐4 inhibitor as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - July 18, 2016 Category: Endocrinology Authors: Nils Ekstr öm, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular Safety of Glucose‐Lowering Agents as Add‐on Medication to Metformin Treatment in Type 2 Diabetes:Report from the Swedish National Diabetes Register (NDR)
Conclusions: This nationwide observational study showed that second‐line treatment with TZD and DPP‐4i as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - May 31, 2016 Category: Endocrinology Authors: Nils Ekström, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research

Comparative cardiovascular safety of glucagon ‐like peptide‐1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RAs with other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to exclude large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - May 1, 2016 Category: Endocrinology Authors: E. Patorno, B. M. Everett, A. B. Goldfine, R. J. Glynn, J. Liu, C. Gopalakrishnan, S. C. Kim Tags: ORIGINAL ARTICLE Source Type: research

Comparative Cardiovascular Safety of Glucagon‐Like Peptide‐1 Receptor Agonists versus Other Antidiabetic Drugs in Routine Care: a Cohort Study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RA versus other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to rule out large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - March 23, 2016 Category: Endocrinology Authors: Elisabetta Patorno, Brendan M. Everett, Allison B. Goldfine, Robert J. Glynn, Jun Liu, Chandrasekar Gopalakrishnan, Seoyoung C. Kim Tags: Original Article Source Type: research

Relationship of glycaemic control and hypoglycaemic episodes to 4‐year cardiovascular outcomes in people with type 2 diabetes starting insulin
ConclusionsOngoing poorer glucose control was associated with CV events; hypoglycaemia was not associated with CV‐specific/all‐cause death.
Source: Diabetes, Obesity and Metabolism - December 23, 2015 Category: Endocrinology Authors: N. Freemantle, N. Danchin, F. Calvi‐Gries, M. Vincent, P. D. Home Tags: ORIGINAL ARTICLE Source Type: research

Relationship of glycaemic control and hypoglycaemic episodes to 4‐year CV outcomes in people with type 2 diabetes starting insulin
ConclusionsOngoing poorer glucose control was associated with CV events; hypoglycaemia was not associated with CV/all‐cause death.
Source: Diabetes, Obesity and Metabolism - October 29, 2015 Category: Endocrinology Authors: N. Freemantle, N. Danchin, F. Calvi‐Gries, Maya Vincent, P. D. Home Tags: ORIGINAL ARTICLE Source Type: research

Case–control study of second‐line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke
ABSTRACT We conducted a population‐based case–control study to assess the myocardial infarction (MI) and stroke risks associated with sulfonylureas and insulin when used in combination with metformin. Cases had type 2 diabetes and used metformin + insulin or metformin + sulfonylureas at the time of a first MI or first stroke from 1995–2010; controls used the same treatment combinations and were randomly sampled from the same population. MI and stroke diagnoses and potential confounders were validated by medical record reviews. Compared with metformin + sulfonylurea, metformin + insulin was associated ...
Source: Diabetes, Obesity and Metabolism - July 14, 2015 Category: Endocrinology Authors: James S. Floyd, Kerri L. Wiggins, Colleen M. Sitlani, James H. Flory, Sascha Dublin, Nicholas L. Smith, Susan R. Heckbert, Bruce M. Psaty Tags: Research Letter Source Type: research

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ConclusionThe CV risk factors of participants in TECOS are reasonably controlled, but differences in CV risk management according to region, sex and history of disease exist. This diversity will enhance the generalizability of the trial results.
Source: Diabetes, Obesity and Metabolism - February 13, 2015 Category: Endocrinology Authors: M. A. Bethel, J. B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, Tags: ORIGINAL ARTICLE Source Type: research

Regional, age, and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ConclusionCV risk factors of TECOS participants are reasonably controlled on average, but differences in CV risk management according to region, sex, and history of prior disease exist. This diversity will enhance generalizability of the trial results.
Source: Diabetes, Obesity and Metabolism - January 20, 2015 Category: Endocrinology Authors: M. A. Bethel, J.B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, Tags: ORIGINAL ARTICLE Source Type: research